Maiva Pharma Private Limited

Maiva Pharma Private Limited, established on February 5, 1993, is a privately held pharmaceutical company headquartered in Bangalore North, Karnataka, India. The company operates under the Corporate Identification Number (CIN) U24231KA1993PTC013976 and is registered with the Registrar of Companies, Bangalore. As of the latest available data, Maiva Pharma has an authorized capital of ₹310.3 million and a paid-up capital of ₹138.4 million.

In the fiscal year ending March 31, 2025, Maiva Pharma reported a total revenue of ₹1,000 million, marking a 28.82% increase from the previous year. The company's net worth also saw a significant rise of 36.72% during the same period. The workforce comprises approximately 751 professionals, reflecting the company's substantial operational scale. Maiva Pharma's official website is www.maivapharma.com.

Maiva Pharma's primary manufacturing facility is located in Hosur, Tamil Nadu, approximately 70 kilometers south of Bengaluru International Airport and 310 kilometers east of Chennai Port. The plant spans 5 acres and is equipped with four manufacturing lines capable of producing both aseptically filled and terminally sterilized products. The facility has received approvals from the US FDA and EU GMP, underscoring its compliance with international quality standards.

In 2024, Maiva Pharma expanded its manufacturing capabilities by establishing Maiva Life Sciences (MLS), a fully owned subsidiary. MLS is a state-of-the-art sterile injectable manufacturing facility under development in Shoolagiri, Hosur. The site is planned to house six manufacturing lines in Phase 1, designed to support advanced sterile injectable production capabilities.

Dr. Bhaskar Krishna serves as the Managing Director and Chief Executive Officer of Maiva Pharma. Since joining the company in 2013, Dr. Krishna has been instrumental in expanding Maiva Pharma's presence in regulated markets such as Canada, the European Union, and Australia. His leadership has facilitated the company's entry into these markets and accelerated the inspection process by Health Canada, followed by EU inspection and approval.

Mr. Shivananda Hegde holds the position of Chief Financial Officer and Company Secretary. Joining Maiva Pharma in 2007, Mr. Hegde has played various roles within the organization, from Financial Controller to Company Secretary. In addition to his responsibilities as CFO and Company Secretary, he also heads the Human Resource department.

Maiva Pharma has established a significant presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facility in Hosur, Tamil Nadu, has received approvals from the US FDA and EU GMP, demonstrating compliance with stringent international quality standards.

In the United States, Maiva Pharma has secured 19 Abbreviated New Drug Application (ANDA) approvals, indicating a strong foothold in the generic pharmaceutical market. The company's expansion into the European Union and Australia further underscores its commitment to meeting global regulatory requirements and delivering quality pharmaceutical products.

Maiva Pharma has also made strategic inroads into emerging markets, including regions in Africa, Latin America, and Southeast Asia. The company's adherence to WHO prequalification standards has facilitated access to these markets, enabling the supply of quality pharmaceutical products to a broader global audience.

Maiva Pharma's geographic strategy reflects a balanced approach to market diversification. The company's significant presence in regulated markets such as the United States, European Union, and Australia mitigates concentration risk and demonstrates a strategic direction focused on global expansion. The establishment of Maiva Life Sciences in Shoolagiri, Hosur, further indicates the company's commitment to enhancing its manufacturing capabilities and market reach.

Maiva Pharma's manufacturing facility in Hosur, Tamil Nadu, is registered with the US FDA, indicating compliance with US regulatory standards. The company has secured 19 ANDA approvals, reflecting its active participation in the US generic pharmaceutical market. While specific details regarding Drug Master File (DMF) filings and inspection history are not publicly disclosed, the company's adherence to US FDA standards suggests a robust regulatory standing.

Maiva Pharma's manufacturing facility has received approvals from the European Union's Good Manufacturing Practice (EU GMP) standards, demonstrating compliance with stringent European quality requirements. Additionally, the company's adherence to WHO prequalification standards facilitates access to various international markets, including those in Africa, Latin America, and Southeast Asia.

Maiva Pharma operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company's manufacturing facility in Hosur, Tamil Nadu, is registered with the CDSCO, ensuring compliance with Indian pharmaceutical manufacturing standards. Specific details regarding state drug controller approvals and export No Objection Certificates (NOCs) are not publicly disclosed.

As of March 28, 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to Maiva Pharma by regulatory authorities. This absence suggests a favorable regulatory standing for the company.

Maiva Pharma operates in a competitive landscape with several key players in the pharmaceutical industry. While specific market share data is not publicly disclosed, the company's significant presence in regulated markets such as the United States, European Union, and Australia positions it as a notable competitor. The establishment of Maiva Life Sciences in Shoolagiri, Hosur, further enhances its manufacturing capabilities, potentially strengthening its competitive position.

Maiva Pharma's key differentiators include its specialized focus on sterile injectables, adherence to international quality standards, and a robust manufacturing facility with US FDA and EU GMP approvals. The company's commitment to quality, compliance, and ethical business practices has earned it recognition in regulated markets such as the United States, European Union, and Australia.

Maiva Pharma's current strategic direction emphasizes the development and manufacturing of sterile injectables, with a focus on expanding its presence in regulated markets. The establishment of Maiva Life Sciences in Shoolagiri, Hosur, indicates a forward-looking approach to enhancing manufacturing capabilities and market reach. The company's adherence to international quality standards and its expansion into emerging markets reflect a strategic vision aimed at sustainable growth and global competitiveness.

Maiva Pharma has demonstrated a strong track record in pharmaceutical manufacturing, with a focus on sterile injectables. The company's manufacturing facility in Hosur, Tamil Nadu, has received approvals from the US FDA and EU GMP, underscoring its compliance with international quality standards. The establishment of Maiva Life Sciences in Shoolagiri, Hosur, further enhances its manufacturing capabilities, indicating a commitment to meeting global demand.

Importers should verify the following certifications when considering Maiva Pharma as a supplier:

• US FDA Registration: Confirm the company's registration status with the US FDA to ensure compliance with US regulatory standards.

• EU GMP Certification: Verify the EU GMP certification to ensure adherence to European manufacturing standards.

• WHO Prequalification: Check for WHO prequalification status to facilitate access to various international markets.

These certifications can typically be verified through the respective regulatory bodies' official websites or by contacting Maiva Pharma directly.

When conducting due diligence on Maiva Pharma, consider the following steps:

• Regulatory Compliance: Verify the company's certifications and approvals from relevant regulatory authorities.

• Financial Health: Review the company's financial statements to assess profitability and financial stability.

• Manufacturing Capabilities: Evaluate the capacity and capabilities of the manufacturing facility, including any recent expansions.

• Quality Assurance: Assess the company's quality control processes and adherence to international standards.

• Market Reputation